Form 4: MAIA Biotechnology Director Louie Ngar Yee Acquires Shares and Warrants

Director Louie Ngar Yee purchased 170,940 shares of MAIA Biotechnology at $1.17 per share and warrants exercisable at $1.30, increasing his direct holdings.

Summary

• On March 14, 2024, Louie Ngar Yee, a director of MAIA Biotechnology, Inc., acquired 170,940 shares of common stock at a price of $1.17 per share.
• The purchase was made pursuant to a Securities Purchase Agreement dated March 11, 2024, and the shares were issued under the Issuer's 2021 Equity Incentive Plan.
• Yee also acquired warrants to purchase 170,940 shares of common stock at an exercise price of $1.30.
• These warrants were also purchased under the Securities Purchase Agreement dated March 11, 2024, and are considered options issued under the Issuer's 2021 Equity Incentive Plan.
• The options are exercisable starting September 14, 2024, and expire on September 14, 2029.
• Following the transaction, Yee directly owns 1,147,524 shares of MAIA Biotechnology.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of shares and warrants can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding 10% or more of a company's shares) buy or sell stock in their own companies. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The purchase of shares by a director could positively influence shareholder sentiment.

Key Dates